+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06704672

Evaluating the Accu-Chek SmartGuide Continuous Glucose Monitoring Device Compared to Self-Monitoring in Adults with Type 1 and Type 2 Diabetes

Led by Hoffmann-La Roche · Updated on 2026-10-26

270

Participants Needed

20

Research Sites

28 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the impact of the Accu-Chek SmartGuide continuous glucose monitoring CGM device in adults with Type 1 or insulin-dependent Type 2 diabetes who use multiple daily insulin injections. The trial compares the time their blood glucose levels stay within the target range of 70 to 180 mgdL when using the CGM device versus traditional self-monitoring of blood glucose SMBG. This open-label, randomized study aims to gather data on glucose management improvements with the new device. Participants are assigned to one of two groups one group uses the Accu-Chek SmartGuide CGM solution, which includes a sensor, a device, and smartphone apps that provide real-time glucose readings and data analysis. The control group continues using SMBG with a blinded CGM sensor during assessment periods, meaning they cannot see real-time glucose data. The study includes baseline and multiple assessment periods over 26 weeks to measure changes in glucose control markers. During the study, participants will have their blood glucose levels monitored and compared across different periods using the CGM or SMBG methods. Researchers will collect data on time spent within glucose target ranges, hypoglycemia and hyperglycemia events, average glucose levels, insulin doses, carbohydrate intake, and questionnaire scores related to diabetes distress and fear of hypoglycemia. The study lasts approximately 27 weeks, including baseline and three assessment periods, with multiple visits and data collection to understand the devices impact on glucose management.

CONDITIONS

Brief Title

Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus

Research Team

S

Study ID Reference: DC000129 Roche Diabetes Care Poland and Turkey

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here